Transplantation, AutologousHematopoietic Stem Cell TransplantationBone Marrow TransplantationTransplantation, HomologousTransplantation ConditioningWhole-Body IrradiationPeripheral Blood Stem Cell TransplantationGraft vs Host DiseaseCombined Modality TherapyBone MarrowAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeCyclophosphamideBone Marrow CellsDisease-Free SurvivalHematologic NeoplasmsTransplantation ChimeraStem Cell TransplantationTissue DonorsLiver TransplantationHistocompatibility TestingMyeloablative AgonistsGraft SurvivalLeukemiaAntineoplastic AgentsHistocompatibilityBusulfanLymphoma, Non-HodgkinHematopoietic Stem CellsRecurrenceRetrospective StudiesAnemia, AplasticSurvival AnalysisUnrelated DonorsKidney TransplantationImmunosuppressive AgentsLeukemia, Myeloid, AcuteTime FactorsBone and BonesSurvival RateRemission InductionSalvage TherapyGraft RejectionCord Blood Stem Cell TransplantationGraft vs Tumor EffectHematopoiesisHLA AntigensFollow-Up StudiesPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation ImmunologyBone Marrow PurgingAcute DiseaseTransplantation, IsogeneicMyelodysplastic SyndromesLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrognosisGraft vs Leukemia EffectVidarabineHeart TransplantationHematologic DiseasesChemotherapy, AdjuvantChimerismCell TransplantationImmunosuppressionHepatic Veno-Occlusive DiseaseMice, Inbred C57BLT-LymphocytesCyclosporineLung TransplantationSiblingsMultiple MyelomaLeukemia, MyeloidLymphocyte DepletionBone Marrow DiseasesHodgkin DiseaseLymphocyte TransfusionTransplantationFatal OutcomeRisk FactorsSevere Combined ImmunodeficiencyMelphalanOrgan TransplantationRadiation ChimeraCytomegalovirus InfectionsProspective StudiesDonor SelectionAntilymphocyte SerumEtoposideAntigens, CD34LymphomaLiving DonorsCarmustineColony-Forming Units AssayCytarabineGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationCell DifferentiationBone Marrow ExaminationFlow CytometryDose-Response Relationship, Drug